Citations

3636 total record number
147 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by type of cell/animal/assay/protein/research or publication.

Page 659 out of 728

Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome

Karauzum, H;Chen, G;Abaandou, L;Mahmoudieh, M;Boroun, AR;Shulenin, S;Devi, VS;Stavale, E;Warfield, KL;Zeitlin, L;Roy, CJ;Sidhu, SS;Aman, MJ;
Product: LPS from Escherichia coli O55:B5

Bacterial Superantigens and Endotoxin:

... Lipopolysaccharide (LPS; Escherichia coli 055:B5) was purchased from List Biological Laboratories, Inc. (Campbell, CA) and reconstituted with PBS prior to use. ...

NOTE:  At the time this paper was written, Product #203 (5mg - LPS from Escherichia coli O55:B5) was utilized.

Product #203 (5 mg - LPS from Escherichia coli O55:B5) is no longer sold.

Product #203A (2.5 mg - LPS from Escherichia coli O55:B5) is available for purchase.

PubMed ID: 22645125

Mammalian DNA is an endogenous danger signal that stimulates local synthesis and release of complement factor B

Kaczorowski, DJ;Scott, MJ;Pibris, JP;Afrazi, A;Nakao, A;Edmonds, RD;Kim, S;Kwak, JH;Liu, Y;Fan, J;Billiar, TR;
Product: ULTRA PURE LPS from Escherichia coli O111:B4

Reagents:

... Ultrapure lipopolysaccharide (LPS) (Escherichia coli 0111:B4, TLR4 lig- and) was purchased from List Biological Laboratories, Inc. (Vandell Way, CA, USA). ...

Results - DNA Stimulates Factor B Synthesis and Release by Macrophages:

Early upregulation of factor B occurs after ischemic tissue injury. However, the endogenous molecules that stimulate factor B production in the setting of ischemic tissue injury have not been identified. We have previously shown that microbial ligands, including LPS and polyinosine–polycytidylic acid (poly I:C) stimulate dynamic synthesis and release of factor B by macrophages (26). We next sought to test the hypothesis that one of several known endogenous mediators of inflammation known to activate patternrecognition receptors would stimulate factor B synthesis. Because we previously found that activation of TLR4 signaling by LPS resulted in synthesis of factor B in macrophages, we therefore studied the effect of several endogenous molecules that have been identified as activators of TLR4 signaling (33–35). As previously observed, stimulation of RAW264.7 macrophages with LPS resulted in upregulation of factor B mRNA (9.9-fold, p<0. 001). However, no significant upregulation of factor B was observed after stimulation with fibrinogen, heparan sulfate or HMGB1 at known stimulatory concentrations (Figure 1). ...

PubMed ID: 22526919

CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species

Yeo, YA;Martínez Gómez, JM;Croxford, JL;Gasser, S;Ling, EA;Schwarz, H;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

EAE induction:

... CD137L-/- mice were a gift from Amgen and bred in-house under pathogen-free conditions. Mice were injected subcutaneously with 100 μg of myelin oligodendrocyte glycoprotein peptide fragment 35-55 (MOG35-55) (Sigma-Aldrich) and 1 mg heat-killed Mycobacterium tuberculosis H37RA (Difco) emulsified in complete Freund’s adjuvant. Pertussis toxin (200 ng in PBS; List Biological Laboratories) was injected intraperitoneally on days 0 and 2 after immunization. ...

Author did not specify which List Labs Pertussis Toxin was utilized.  List Labs provides Product #180 - Pertussis Toxin from B. pertussis, Lyophilized in Buffer and Product #181 - Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free).

PubMed ID: 22799524

Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ

Perry, DJ;Yin, Y;Telarico, T;Baker, HV;Dozmorov, I;Perl, A;Morel, L;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Experimental autoimmune encephalomyelitis:

Experimental autoimmune encephalomyelitis was induced in 4-mo-old male B6 or B6.Sle1c2 mice. On day 0, mice received an emulsion of 50 mg myelin oligodendrocyte glycoprotein peptide sequence 35–55 and 500 mg Mycobacterium tuberculosis (Difco) in IFA (Sigma-Aldrich) via s.c. injections at the base of the tail. In addition, 500 ng pertussis toxin (List Biologicals) was administered i.p. on days 0 and 2. ...

Author did not specify which List Labs Pertussis Toxin was utilized.  List Labs provides Product #180 - Pertussis Toxin from B. pertussis, Lyophilized in Buffer and Product #181 - Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free).

PubMed ID: 22711888

Oral administration of fermented red ginseng suppressed ovalbumin-induced allergic responses in female BALB/c mice

Lee, EJ;Song, MJ;Kwon, HS;Ji, GE;Sung, MK;
Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

... cholera toxin was from List Laboratories; ...

Intragastric antigen sensitization and treatment:

Sensitization was performed by 20 [micro]g OVA gavage with 10 [micro]g cholera toxin in 0.2 ml saline for 5 times once a week using a stainless steel blunt feeding needle. Mice in the non-sensitized control group received saline. Experimental diet included 0.1% or 0.3% red ginseng or fermented red ginseng. Mice were fed the experimental diet for 8 weeks starting at 1 week before the initial sensitization. ...

 

Author did not specify which Cholera toxin was utilized.  List Labs Product #101B/C - Cholera Toxin from Vibrio Cholerae has been discontinued; however, List Labs still provides Product #100B - Cholera Toxin (AZIDE-FREE) from Vibrio cholerae.  

To follow, are our recommendations for transitioning from Product #101B/C to Product #100B:

Product #101B, Cholera Toxin from Vibrio cholerae (1 mg), has been discontinued.  Product #100B, Cholera Toxin (AZIDE-FREE) from Vibrio cholerae, may be substituted for Product #101B, if the user accounts for the formulation differences.  Both products contain the same quantity of toxin per vial (1.0 mg).  For Product #100B, reconstitution with 1.0 mL of water results in a 1 mg/mL toxin solution in a buffer with the following component concentrations:  0.05 M Tris, 0.2 M NaCl, 0.001 M Na2EDTA at pH 7.5.  For Product #101B, reconstitution with half that amount of water (0.5 mL) resulted in a 2 mg/mL toxin solution with the same concentrations of the buffer components, and in addition, Product #101B contained 0.003 M NaN3.  The user may add the sodium azide preservative to product #100B, if desired.

Product #101C, Cholera Toxin from Vibrio cholerae (2 mg), has been discontinued.  Product #100B, Cholera Toxin (AZIDE-FREE) from Vibrio cholerae, may be substituted for #101C, if the researcher accounts for the formulation differences.  While Product #101C contained 2.0 mg per vial, Product #100 contains 1.0 mg per vial.  When Product #100B is reconstituted with 1.0 mL of water, the resulting 1 mg/mL toxin solution will have buffer components with the following concentrations:  0.05 M Tris, 0.2 M NaCl, 0.001 M Na2EDTA at pH 7.5.  For Product #101C, reconstitution with less than half that amount of water (0.4 mL) resulted in a 5 mg/mL toxin solution in the same buffer, and in addition, Product #101C contained 0.003 M NaN3.  The user may add the sodium azide preservative to product #100B, if desired. 

Large quantities of Product #101B or Product #101C may be obtained through Bulk Requests and Customer Orders

PubMed ID: 22608480